Position in LLY
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$49,080,558,871
New position
Shares Held
53,361,774
first reported quarter
Ownership
5.67%
of shares outstanding
% of Portfolio
1.28%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026VANGUARD CAPITAL MANAGEMENT LLC holds $184,375,246,679 across 13 Drug Manufacturers - General names. LLY ranks #1 (26.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
This page
|
53,361,774 | $49,080,558,871 | |
| 2 | JNJ |
Johnson & Johnson
|
156,605,370 | $38,280,616,642 | |
| 3 | ABBV |
AbbVie Inc.
|
114,880,324 | $24,985,321,666 | |
| 4 | MRK |
Merck & Co., Inc.
|
160,987,624 | $19,365,201,290 | |
| 5 | AMGN |
Amgen Inc
|
35,014,232 | $12,319,757,529 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
80,654,776 | $11,240,856,131 | |
| 7 | PFE |
Pfizer Inc
|
369,430,012 | $10,373,594,736 | |
| 8 | AZN |
Astrazeneca PLC
|
45,040,142 | $8,882,816,805 |
All Filings in LLY
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $56,377,858,610 | 61,295,605 | Shares | Sole | 2026-05-01 | |
| 2026-03-31 | $49,080,558,871 | 53,361,774 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||